General Dosing Information
There is no data available on the interchangeability of the Pfizer-BioNTech COVID-19 vaccine with other COVID-19 vaccines to complete the vaccination series. Patients who receive the first dose of Pfizer-BioNTech COVID-19 vaccine should receive a second dose of Pfizer-BioNTech COVID-19 vaccine to complete the vaccination series.
There is no available information on coadministration of the Pfizer-BioNTech COVID-19 vaccine with other vaccines. During clinical trials, the Pfizer-BioNTech COVID-19 vaccine protocol allowed influenza vaccines to be administered at least 14 days before or after the COVID-19 vaccine doses.[66160]
Advisory Committee on Immunization Practices (ACIP) Interim Recommendations for Vaccine Allocation (Phase 1a)
In the initial phase of the vaccination program, it is recommended that both health care personnel and residents of long-term care facilities (LTCFs) are the first to be offered the COVID-19 vaccine.
Health care personnel are defined as paid and unpaid persons serving in health care settings who have the potential for direct or indirect exposure to patients or infectious materials.
Residents of LTCFs are defined as adults who reside in facilities providing services, including medical and personal care, to those who are not able to live independently.
Priority may be given to health care personnel who work in close proximity (within 6 feet) to other people.
Priority may also be given to residents and health care personnel in skilled nursing facilities due to high medical acuity and COVID-19-associated mortality among residents in these settings.[66165]
INVESTIGATIONAL USE: For the prevention of coronavirus disease 2019 (COVID-19): Intramuscular dosage (Pfizer-BioNTech COVID-19 vaccine): Adults: 0.3 mL (30 mcg) IM for 2 doses administered 21 days apart.[66080] Adolescents 16 years and older: 0.3 mL (30 mcg) IM for 2 doses administered 21 days apart. Of note, Emergency Use Authorization is based on extrapolation of adult safety and efficacy data.[66080]
Maximum Dosage Limits
Adults 0.3 mL/dose IM.
Geriatric 0.3 mL/dose IM.
Adolescents 16 years and older: 0.3 mL/dose IM. 15 years and younger: safety and efficacy have not been established.
Children Safety and efficacy have not been established.
Infants Safety and efficacy have not been established.
Neonates Safety and efficacy have not been established.
Patients with Hepatic Impairment Dosing Specific guidelines for dosage adjustments in hepatic impairment are not available; it appears that no dosage adjustments are needed.
Patients with Renal Impairment Dosing Specific guidelines for dosage adjustments in renal impairment are not available; it appears that no dosage adjustments are needed.
†Off-label indication
Cookies são usados neste site. Para recusar ou saber mais, visite nosso conheça nosso aviso de cookies.
Copyright © 2024 Elsevier, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies.